Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8⁺ T-cell Recognition of a Retroviral Antigen.

ABSTRACT: Antibody-cytokine complexes may offer new tools to treat cancer. Here, we show how TNF-linked antibodies, which recognize tumor-selective splice isoforms of fibronectin (F8-TNF), can be exploited to eradicate sarcomas in immunocompetent mice. We treated mice bearing WEHI-164 fibrosarcoma with a combination of F8-TNF and doxorubicin, curing the majority of treated animals (29/37). Notably, cured mice were resistant to rechallenge not only by WEHI-164 cells but also heterologous C51 or CT26 colorectal tumor cells in a CD8⁺ T-cell-dependent process. Mechanistic analyses revealed that each tumor cell line presented AH1, a common endogenous retroviral peptide. Numbers of AH1-specific CD8⁺ T cells exhibiting cytotoxic capacity were increased by F8-TNF plus doxorubicin treat

SUBMITTER: Probst P 

PROVIDER: S-EPMC5557340 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature